Xeris Biopharma Holdings Inc [XERS] stock prices are down -1.01% to $4.90 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The XERS shares have gain 13.95% over the last week, with a monthly amount glided 17.79%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Xeris Biopharma Holdings Inc [NASDAQ: XERS] stock has seen the most recent analyst activity on November 11, 2024, when Piper Sandler downgraded its rating to a Neutral but kept the price target unchanged to $3 for it. Previously, Oppenheimer started tracking the stock with Outperform rating on March 28, 2024, and set its price target to $5. On August 28, 2023, Craig Hallum initiated with a Buy rating and assigned a price target of $4.50 on the stock. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $4 on October 21, 2022. Craig Hallum initiated its recommendation with a Buy and recommended $6.50 as its price target on April 28, 2022. SVB Leerink started tracking with a Outperform rating for this stock on November 17, 2021, and assigned it a price target of $6. In a note dated October 29, 2021, H.C. Wainwright initiated an Buy rating and provided a target price of $4 on this stock.
The stock price of Xeris Biopharma Holdings Inc [XERS] has been fluctuating between $1.77 and $6.07 over the past year. Currently, Wall Street analysts expect the stock to reach $4 within the next 12 months. Xeris Biopharma Holdings Inc [NASDAQ: XERS] shares were valued at $4.90 at the most recent close of the market. An investor can expect a potential drop of -18.37% based on the average XERS price forecast.
Analyzing the XERS fundamentals
The Xeris Biopharma Holdings Inc [NASDAQ:XERS] reported sales of 222.55M for trailing twelve months, representing a surge of 47.94%. Gross Profit Margin for this corporation currently stands at 0.79% with Operating Profit Margin at -0.17%, Pretax Profit Margin comes in at -0.28%, and Net Profit Margin reading is -0.27%. To continue investigating profitability, this company’s Return on Assets is posted at -0.17, Equity is 2.54 and Total Capital is -0.15. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -9.17.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.82 points at the first support level, and at 4.73 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.01, and for the 2nd resistance point, it is at 5.11.
Ratios To Look Out For
It’s worth pointing out that Xeris Biopharma Holdings Inc [NASDAQ:XERS]’s Current Ratio is 1.72. Further, the Quick Ratio stands at 1.17, while the Cash Ratio is 0.71. Considering the valuation of this stock, the price to sales ratio is 3.53.
Transactions by insiders
Recent insider trading involved Fairley Ricki Louise, Director, that happened on May 09 ’25 when 56667.0 shares were purchased., Hecht Beth completed a deal on Mar 20 ’25 to sell 40000.0 shares. Meanwhile, Officer Hecht Beth bought 40000.0 shares on Mar 20 ’25.
